
Signatur Biosciences: Affordable, rapid blood tests for complex diseases, including breast cancer.
Founded with a mission to make precision diagnostics more accessible, Signatur Biosciences focuses on developing affordable and rapid blood tests for complex diseases, starting with breast cancer prognosis. Their innovative molecular technology enables local hospital labs to perform diagnostics that traditionally required complex centralized facilities, significantly reducing turnaround time and costs. By leveraging widely accessible PCR equipment, Signatur Biosciences aims to democratize high-quality healthcare diagnostics globally.
Notable affiliated individuals and investors have supported Signatur Biosciences in its journey to revolutionize medical diagnostics. The company has achieved significant milestones, including the development of diagnostic kits that reduce the time for breast cancer prognosis from over three weeks to just a few days at half the traditional cost. This breakthrough has had a profound impact on patient care, enabling quicker and more affordable access to life-saving information.

Digistain
digistain.co.uk

Prompt Diagnostics
prompt-dx.com

Probius
probius.bio

Aperture Bio
aperture.bio

Harbinger Health

Nanopath
nanopathdx.com

Babson Diagnostics
babsondx.com

Liquid Biotech

Epinoma
epinoma.com

Salish Bioscience

Hawkeye Bio
hawkeyebio.com

FYR Diagnostics
fyrdiagnostics.com

Valtari Bio

E25Bio
e25bio.com

Biorosa Technologies
biorosa.com
Companies similar to Signatur Biosciences include Digistain, Prompt Diagnostics, Probius and Aperture Bio.
Signatur Biosciences was founded in 2022.
Signatur Biosciences' headquarters is located in New York City, NY, US.
Signatur Biosciences' most recent funding round was for $500k (USD) in August 2022.
As of Aug 22, 2022, Signatur Biosciences has raised a total of $500k (USD).
Signatur Biosciences has 2 employees as of Feb 24, 2024.